| 摘要: |
| 目的 通过梳理分析北京、上海、广东、辽宁、云南、新疆等14个省份药品经营多仓协同政策实施文件,为药品监管部门及药品经营企业提供政策参考,助力行业高质量发展。方法 构建以政策文件发布时间、许可要求(申请主体、许可方式、协同范围、协同方式)和协同责任(组织保障、质量体系建设、计算机系统要求、流程优化)三大核心九项维度的分析框架,对各省政策文件进行对比,提炼共性和差异点,分析监管难点并提出优化建议。结果 全国大部分省份通过政策性文件、通知或征求意见稿形式推动开展多仓协同工作。在坚守药品质量安全底线、明确各方责任、管控关键风险环节等方面形成共性规则,但在参与主体资质、协同范围、指令执行模式等方面存在区域差异,且全国层面缺乏统一政策框架与明确法规依据。结论 药品经营多仓协同模式在激发药品流通市场活力的同时,也因各地规则差异与政策“碎片化”等因素,其持续发展受到制约。通过多角度对比分析各地药品经营多仓协同政策文件,提出有利于行业规范健康发展的建议,为监管部门科学施策提供支持。 |
| 关键词: 药品经营 多仓协同 政策分析 对比分析 |
| DOI:10.13506/j.cnki.jpr.2026.07.018 |
| 基金项目: |
|
收稿日期:2026-04-10
修回日期:2026-04-27
出版日期:2026-07-31
|
|
| Comparative analysis of multi-warehouse collaboration policy of drug business in some provinces of China |
| LI Haifeng1,ZHAO Caihong1,LIN Xiaoming1,CHEN Gang2,RAN Daqiang1,SUN Bing3,XUE Runpu4 |
| (1.Shandong Food and Drug Evaluation and Inspection Center, Jinan 250014, China; 2.Shandong Institute for Food and Drug Control, Jinan 250101, China; 3.Yuncheng County Market Supervision Administration, Yuncheng 274700, China; 4.Shandong Medical And Pharmaceutical University, Yantai 264003, China) |
| Abstract: |
| Objective To provide policy references for drug regulatory authorities and drug distribution enterprises by analyzing the implementation documents of multi-warehouse collaboration policies in 14 provinces including Beijing, Shanghai, Guangdong, Liaoning, Yunnan, and Xinjiang, thereby promoting the high-quality development of the industry. Methods An analytical framework was constructed with three core aspects and nine dimensions, including the release time of policy documents, licensing requirements (application subjects, licensing methods, collaboration scope, and collaboration methods), and collaboration responsibilities (organizational guarantees, quality system construction, computer system requirements, and process optimization). The policy documents of various provinces were compared to extract commonalities and differences, analyze regulatory difficulties, and propose optimization suggestions.Results Most provinces across the country have promoted multi-warehouse collaboration through policy documents, notices, or draft opinions. Common rules have been formed in terms of adhering to the bottom line of drug quality and safety, clarifying the responsibilities of all parties, and controlling key risk links. However, there are regional differences in aspects such as the qualifications of participating entities, collaboration scope, and instruction execution models. Moreover, there is a lack of a unified policy framework and clear legal basis at the national level.Conclusion While the multi-warehouse collaboration model in drug distribution has stimulated the vitality of the drug circulation market, its continuous development is constrained by factors such as regional rule differences and policy fragmentation. Through multi-angle comparative analysis of the multi-warehouse collaboration policy documents of various provinces, suggestions that are conducive to the standardized and healthy development of the industry are proposed to support the scientific policy-making of regulatory authorities. |
| Key words: Drug business Multi-warehouse collaboration Policy analysis Thoughts and suggestions |